Core Viewpoint - The announcement details the expected daily related transactions for the year 2026 by Ningbo SANSING Medical Electric Co., Ltd, indicating that these transactions are necessary for the company's operations and will not adversely affect its independence or financial health [2][14]. Group 1: Daily Related Transactions Overview - The daily related transactions for 2026 do not require shareholder meeting approval [2]. - The expected amount for daily related transactions in 2026 is capped at 220 million yuan [5]. - The board of directors approved the proposal for these transactions during a meeting held on December 30, 2025, with related directors abstaining from voting [3][17]. Group 2: Related Parties and Relationships - The main related party is AUX Group Co., Ltd, which is the controlling shareholder of the company [5][6]. - Other related parties include Ningbo SANSING Technology Co., Ltd and Ningbo AUX Kaiyun Medical Investment Partnership, which are also linked to the company's operations [8][9]. - The financial health of these related parties is stable, indicating a good capacity to fulfill their obligations [12]. Group 3: Transaction Details and Pricing Policy - The daily related transactions include procurement and sales of goods, property services, medical services, and leasing of facilities [12]. - Pricing for these transactions is based on fair market value, ensuring fairness and transparency [13]. Group 4: Impact on the Company - The transactions are aimed at optimizing resource allocation and improving operational efficiency without compromising the company's independence [14]. - The company asserts that these transactions will not negatively impact its financial status or operational results, nor will they harm the interests of minority shareholders [14].

Group 1 - The core point of the article is that Samsung Medical has announced the approval of a proposal regarding expected daily related transactions for the year 2026 during its board meeting [2] - The proposal was passed with the recusal of related directors Shen Guoying, Zheng Jianjiang, and Lv Meng from the voting process [2] - The proposal has also been approved by a special meeting of independent directors [2]

Group 1 - Samsung Medical announced the convening of its 27th meeting of the 6th Board of Directors on December 30, 2025, held both in-person and via communication [1] - The meeting reviewed the proposal regarding the expected daily related transactions for the year 2026 [1]

证券代码：601567 证券简称：三星医疗 公告编号：临 2025-099 宁波三星医疗电气股份有限公司 关于 2026 年度预计日常关联交易的公告 （一）日常关联交易履行的审议程序 宁波三星医疗电气股份有限公司（以下简称"公司"）于2025年12月30日召开公 司第六届董事会第二十七次会议，审议通过了《关于2026年度预计日常关联交易的 议案》，其中关联董事已回避表决，该议案已经独立董事专门会议审议通过。 （二）2025年度日常关联交易的执行情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ● 2026年度日常关联交易无需提交股东大会审议。 ● 关联交易完成后对上市公司的影响：2026年预计发生的日常关联交易系与公 司日常经营相关的关联交易，符合公司生产经营的实际需求。交易价格以市场价格 为基础协商定价，公平合理，对本公司持续经营能力、盈利能力及资产独立性等不 会产生不利影响。此交易不会影响本公司的独立性，公司主要业务不会因此对关联 方形成依赖。 单位：万元 | | | | | 预计金额 | | | -- ...

该议案已经公司独立董事专门会议审议通过。 宁波三星医疗电气股份有限公司（以下简称"公司"）于 2025 年 12 月 25 日以电话、传真、邮件等方式发出召开第六届董事会第二十七次会议的通知，会 议于 2025 年 12 月 30 日在公司会议室以现场及通讯方式召开。会议应到董事 9 人，实到董事 9 人，会议由董事长沈国英女士主持，公司其他高级管理人员列席 了会议，会议的召集和召开符合《公司法》和《公司章程》的有关规定。经与会 董事认真审议并表决，通过了以下议案，形成决议如下： 一、审议通过了关于 2026 年度预计日常关联交易的议案 详见公司披露于上海证券交易所网站（www.sse.com.cn）的《三星医疗关于 2026 年度预计日常关联交易的公告》（公告编号：临 2025-099）。 表决结果：6 票赞成、0 票反对、0 票弃权，3 票回避，关联董事沈国英、郑 坚江、吕萌回避表决。 证券代码：601567 证券简称：三星医疗 公告编号：临 2025-098 宁波三星医疗电气股份有限公司 第六届董事会第二十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏 ...

证券代码：601567 证券简称：三星医疗 公告编号：临2025-097 宁波三星医疗电气股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 975,350.00 | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 80.73% | | 100% 特别风险提示（如有请勾选） | □对外担保总额超过最近一期经审计净资产 担保金额超过上市公司最近一期经审计净 | | 资产 | 50% | | | □对合并报表外单位担保金额达到或超过最 | | | 近一期经审计净资产 30%的情况下 | | | 对资产负债率超过 70%的单位提供担保 | | 其他风险提示（如有） 无 | | 注：表中截至本公告日上市公司及其控股子公司对外担保总额，包含年度已批准的担 保额度内尚未使用额度与担保实际发生余额之和，并非公 ...

三星医疗公告称，近日与浦发银行签订《最高额保证合同》，为全资子公司奥克斯智能科技提供1亿元 银行授信担保，期限自2025年12月26日至2030年12月26日。截至公告披露日，公司对其实际担保余额达 44.63亿元（含本次）。公司及控股子公司对外担保总额97.54亿元，占2024年度经审计净资产的 80.73%，无逾期担保。该担保事项已履行必要审批程序，总体风险可控。 ...

Group 1 - The high-pressure oxygen chamber concept declined by 0.92%, ranking among the top declines in the concept sector, with companies like Innovation Medical, Aoyang Health, and Yinkang Life experiencing significant drops [1] - Among the concept stocks, Jinling Pharmaceutical, Tiedao Heavy Industry, and Hangyang Co. saw increases of 2.93%, 0.77%, and 0.26% respectively [1] - The top-performing concept sectors today included Hainan Free Trade Zone with a rise of 4.32%, and various metal sectors such as zinc and lead, which increased by 3.61% and 3.30% respectively [1] Group 2 - The high-pressure oxygen chamber concept experienced a net outflow of 199 million yuan, with six stocks seeing significant outflows, led by Innovation Medical with a net outflow of 132 million yuan [1] - Other companies with notable net outflows included Hangyang Co. and Yinkang Life, with outflows of 39.31 million yuan and 12.35 million yuan respectively [1] - Conversely, Aoyang Health, Jinling Pharmaceutical, and Dahu Co. were among the stocks with net inflows, receiving 2.49 million yuan, 2.04 million yuan, and 0.47 million yuan respectively [1]

Core Viewpoint - The company is focusing on its "globalization and new energy" strategy, with ongoing developments in overseas markets and new energy business segments [1] Group 1: New Energy Strategy - The company’s new energy products include photovoltaic transformers, charging piles, inverters, and energy storage solutions [1] - The photovoltaic transformer has received domestic first-set certification, while the charging pile business secured its first European order in Sweden worth 124 million yuan [1] - The inverter business has made continuous breakthroughs in the Brazilian market, and energy storage products include low-voltage home storage solutions ranging from 5-16 kWh and high-voltage stacked battery packs [1] Group 2: Order Status - As of the end of Q3 2025, the company has a total order backlog of 17.914 billion yuan, representing a year-on-year increase of 14.69% [1] - The overseas distribution order backlog stands at 2.169 billion yuan, showing a significant year-on-year growth of 125.45% [1] Group 3: Product Development - The company is developing intelligent management platforms that integrate self-developed Battery Management Systems (BMS) and Energy Management Systems (EMS), along with AI diagnostics to enhance operational efficiency and energy generation [1]

Core Viewpoint - Samsung Medical (601567) has signed a contract for a smart meter project in Brazil, which is expected to contribute to its revenue in 2024 [1] Group 1: Company Performance - As of December 24, 2025, Samsung Medical's stock closed at 23.16 yuan, reflecting a 0.09% increase from the previous trading day [1] - The company's total market capitalization is 32.545 billion yuan [1] - The stock opened at 23.01 yuan, reached a high of 23.43 yuan, and a low of 22.91 yuan, with a trading volume of 3.29 billion yuan and a turnover rate of 1.01% [1] Group 2: Contract Details - Samsung Medical's wholly-owned subsidiary, Brazil Nansen, has signed a contract with CPFL ENERGIA for the Brazil CPFL smart meter project [1] - The total contract amount is 10,590.99 million Brazilian Reais, approximately 135 million yuan [1] - This contract represents 0.92% of the company's audited operating revenue for the year 2024 [1] Group 3: Risks - The announcement highlights potential risks during the contract execution, including force majeure, adjustments in international trade policies, and exchange rate fluctuations [1]